



## News Release

### **Suven Spends 20.5% of Revenue on R&D PAT up by 48.55% for the year ending March 2011**

HYDERABAD, INDIA (May 30, 2011) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the year ended 31 Mar 2011 as well as quarter ended Mar' 2011. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on May 30, 2011 at Hyderabad.

#### **Financial Highlights for the 4rth Quarter ended Mar' 2011:**

Growth in revenue Rs 4647 lacs vs. Rs 3640 lacs	...	27.66%
Growth in PAT Rs 350 lacs vs. Rs 158 lacs	...	121.54%
Growth in EBIDTA Rs 540 lacs vs. Rs 256 lacs	...	110.73%

#### **Financial Highlights for the full year ended Mar' 2011:**

Growth in revenue Rs 15169 lacs vs. Rs 12980 lacs	...	16.86%
Growth in PAT Rs.1040 lacs vs. Rs 700 lacs	...	48.55%
Growth in EBIDTA Rs 1402 lacs vs. Rs.1305 lacs	...	7.44%

**Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 767 lacs (16.5% on revenue) for the quarter ended Mar' 2011 and Rs. 3114 lacs (20.53% on revenue) for the year ended Mar' 2011 .**

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information on Suven please visit our Web site at <http://www.suven.com>

#### **Safe Harbor Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*